1. A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. Issue 1 (December 2016) Authors: Patel, Charmi; Bailey, Robert; Vijapurkar, Ujjwala; Meininger, Gary; Blonde, Lawrence Journal: BMC health services research Issue: Volume 16:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. (2nd November 2015) Authors: Blonde, Lawrence; Woo, Vincent; Mathieu, Chantal; Yee, Jacqueline; Vijapurkar, Ujjwala; Canovatchel, William; Meininger, Gary Journal: Current medical research and opinion Issue: Volume 31:Number 11(2015:Nov.) Page Start: 1993 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes. (1st February 2018) Authors: Merton, Katherine; Davies, Michael J.; Vijapurkar, Ujjwala; Inman, Doreen; Meininger, Gary Journal: Current medical research and opinion Issue: Volume 34:Number 2(2018) Page Start: 313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. (2nd July 2020) Authors: Yuan, Zhong; DeFalco, Frank; Wang, Lu; Hester, Laura; Weaver, James; Swerdel, Joel N.; Freedman, Amy; Ryan, Patrick; Schuemie, Martijn; Qiu, Rose; Yee, Jacqueline; Meininger, Gary; Berlin, Jesse A.; Rosenthal, Norman Journal: Current medical research and opinion Issue: Volume 36:Number 7(2020) Page Start: 1117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Canagliflozin for the treatment of adults with Type 2 diabetes. (May 2015) Authors: Meininger, Gary; Canovatchel, William; Polidori, David; Rosenthal, Norm Journal: Diabetes management Issue: Volume 5:Number 3(2015) Page Start: 183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Issue 1 (25th August 2015) Authors: Rosenthal, Norm; Meininger, Gary; Ways, Kirk; Polidori, David; Desai, Mehul; Qiu, Rong; Alba, Maria; Vercruysse, Frank; Balis, Dainius; Shaw, Wayne; Edwards, Robert; Bull, Scott; Di Prospero, Nicholas; Sha, Sue; Rothenberg, Paul; Canovatchel, William; Demarest, Keith Journal: Annals of the New York Academy of Sciences Issue: Volume 1358:Issue 1(2015) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. Issue 4 (December 2016) Authors: Qiu, Rong; Balis, Dainius; Capuano, George; Xie, John; Meininger, Gary Journal: Diabetes therapy Issue: Volume 7:Issue 4(2016) Page Start: 659 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Issue 12 (27th August 2019) Authors: Wang, Lu; Voss, Erica A.; Weaver, James; Hester, Laura; Yuan, Zhong; DeFalco, Frank; Schuemie, Martijn J.; Ryan, Patrick B.; Sun, Don; Freedman, Amy; Alba, Maria; Lind, Joan; Meininger, Gary; Berlin, Jesse A.; Rosenthal, Norman Journal: Pharmacoepidemiology and drug safety Issue: Volume 28:Issue 12(2019) Page Start: 1620 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus. Issue 12 (20th October 2014) Authors: Weir, Matthew R.; Januszewicz, Andrzej; Gilbert, Richard E.; Vijapurkar, Ujjwala; Kline, Irina; Fung, Albert; Meininger, Gary Journal: Journal of clinical hypertension Issue: Volume 16:Issue 12(2014:Dec.) Page Start: 875 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Effect of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, on measurement of serum 1, 5‐anhydroglucitol1 (坎格列净，一种钠‐葡萄糖共转运体2抑制剂，对血清1, 5‐脱水葡萄糖醇测定的影响). (25th February 2014) Authors: Balis, Dainius A.; Tong, Cindy; Meininger, Gary Journal: Journal of diabetes Issue: Volume 6:Number 4(2014:Oct.) Page Start: 378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗